ProTgen was founded by Juan Carlos Zuniga-Pflucker in 2023.

Who are ProTgen's investors?

ProTgen's investors include Eisai Innovation, Inc., FACIT (Fight Against Cancer Innovation Trust), Boehringer Ingelheim Venture Fund.

How much funding has ProTgen raised?

ProTgen has disclosed $8.2M raised across 1 round.

Where is ProTgen headquartered?

ProTgen is headquartered in Toronto.

ProTgen

Toronto · Founded 2023 · 3 known investors

Find your way into ProTgen

Paths you didn't know you had: your email and LinkedIn already hold routes to the ProTgen team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

ProTgen is a clinical-stage biotechnology company developing targeted Notch activators that generate progenitor T cells to restore thymic function and adaptive immune competence. Its work spans ex vivo cell therapy (ProT-096) and in vivo biologic programs (RGT-096).

Biotech Healthtech

Founders & leadership

ProTgen was founded in 2023 by Juan Carlos Zuniga-Pflucker.

Juan Carlos Zuniga-PfluckerFounder

Board

Fei ShenBoard director

Ferdinand MassariBoard director

Investors · 3

Eisai Innovation, Inc.listed by Eisai Innovation, Inc.Cambridge · $5M

FACIT (Fight Against Cancer Innovation Trust)listed by FACIT (Fight Against Cancer Innovation Trust)Toronto · $1.1M

How we know: FACIT (Fight Against Cancer Innovation Trust)'s portfolio page · Not right? Tell us

Boehringer Ingelheim Venture FundreportedIngelheim am Rhein · $16.2M

How we know: open dataset · 5k.vc investor directory · Not right? Tell us

Reported raises · per SEC filings

Form D private placements

$8.2M disclosed across 1 round · 2024

▶$8.2MraisedDec 2024 · 4 investors · Other

Rule 506(b)

Officers, directors & promoters on the filing

Fei ShenDirector
Juan Carlos Zuniga-PfluckerExecutive Officer, Director
Ferdinand MassariDirector

Offering amount: $20M
Amount sold: $8.2M
First sale: Nov 2024
Incorporated: Corporation, Delaware, 2023
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Related companies · 1

PepGenPepGen is a clinical-stage biotech company developing oligonucleotide therapies for neuromuscular and neurological diseases using its Enhanced Delivery Oligonucleotide (EDO) platform to improve tissue penetration and uptake in muscle tissues.

Companies working in the same space as ProTgen.

Frequently asked questions

What does ProTgen do?: ProTgen is a clinical-stage biotechnology company developing targeted Notch activators that generate progenitor T cells to restore thymic function and adaptive immune competence. Its work spans ex vivo cell therapy (ProT-096) and in vivo biologic programs (RGT-096).
Who founded ProTgen?: ProTgen was founded by Juan Carlos Zuniga-Pflucker in 2023.
Who are ProTgen's investors?: ProTgen's investors include Eisai Innovation, Inc., FACIT (Fight Against Cancer Innovation Trust), Boehringer Ingelheim Venture Fund.
How much funding has ProTgen raised?: ProTgen has disclosed $8.2M raised across 1 round.
Where is ProTgen headquartered?: ProTgen is headquartered in Toronto.